The BIO Europe conference this year takes in a variety of hot topics in the life sciences arena. WIPR takes a look, and talks to speaker Perter Homberg about how dealmaking in the industry is changing.
The biotechnology industry is changing. A perfect storm of economic constraints, looming blockbuster patent expirations and reduced government budgets mean that companies in the industry are facing new pressures. How they adapt to the changing environment will dictate whether they prosper in the years to come.
Peter Homberg, partner at Raupach & Wollert-Elmendorff and head of Raupach’s Life Science Practice, will be chairing a panel on IP and deal- making dynamics at the conference. It will look at recent developments in IP law, including the impact of the revisions to US patent law, and consider the future of personalised medicine and bio-marker assisted methods of treatment.
As Homberg points out, “there are some changes in the market that have been triggered by pressure on big pharma – there’s a relatively small new product pipeline, expiring patents for “Block Buster Therapeutics”, and new issues with respect to reimbursement. There’s also pressure on the regulatory side.” Big pharmaceutical companies, he says, have reacted quite naturally to these pressures.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
BIO Europe conference, Peter Homberg